Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 4, 2006, Pages 589-608

  Gemmell, Curtis G ^a   Edwards, David I ^b   Fraise, Adam P ^c   Gould, F Kate ^d   Ridgway, Geoff L ^b   Warren, Rod E ^e  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b City Hospital NHS Trust ^*  (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

^e ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

Author keywords

Evidence based guidelines; Methicillin; Meticillin; MRSA guidelines

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDATE SODIUM; GENTAMICIN; LINEZOLID; MACROLIDE; METICILLIN; NAFCILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM CARRIER; BONE INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; EYE INFECTION; HUMAN; INFECTION CONTROL; INFECTIOUS ARTHRITIS; MEDICAL LITERATURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL TECHNIQUE; TREATMENT FAILURE; UNITED KINGDOM; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; GREAT BRITAIN; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33645119091     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl017     Document Type: Review

References (266)

1. Guidelines for the control of methicillin-resistant Staphylococcus aureus. Report of a combined working party of the Hospital Infection Society and British Society for Antimicrobial Chemotherapy. J Hosp Infect 1986; 7: 193-201.
2. Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. Report of a combined working party of the Hospital Infection Society and British Society for Antimicrobial Chemotherapy. J Hosp Infect 1990; 16: 351-77.
3. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. J Hosp Infect 1998; 39: 253-90.
4. Mangram AJ, Horan TC, Pearson ML et al. Guideline for prevention of surgical site infection. Infect Control Hosp Epidemiol 1999; 20: 247-78.
5. Ministry of Health, New Zealand. Methicillin-resistant Staphylococcus aureus (MRSA) in New Zealand. http://www.moh.govt.nz/cd/mrsa, pp. 1-65. Wellington, New Zealand, 2002 (4 October 2005,date last accessed).
6. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-9.
7. Tacconelli E, Venkataraman I, De Girolami PC et al. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: Distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 2004; 53: 474-9.
8. Calfee DP, Durbin LJ, Germanson TP et al. Spread of methicillin-resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 2003; 24: 422-6.
9. Jernigan JA, Pullen AL, Flowers L et al. Prevalence and risk factors for colonization with methicillin-resistant Staphylococcus aureus at the time of hospital admission. Infect Control Hosp Epidemiol 2003; 24: 409-14.
10. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1819-27.
11. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003; 9: 978-84.
12. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: An e merging pathogen. Infect Control Hosp Epidemiol 2003; 24: 451-5.
13. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K et al. Community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis Journal 2004; 23: 701-6.
14. Boyce JM. Methicillin-resistant Staphylococcus aureus: Detection, epidemiology and control measures. Infect Dis Clin North Am 1989: 3: 901-13.
15. Schentag JJ, Hyatt JM, Carr JR et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control Clin Infect Dis 1998; 26: 1204-14.
16. Shlaes DM, Gerding DN, John JF et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18: 275-91.
17. Boyce JM. Understanding and controlling methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol 2002; 23: 485-7.
18. Fukutsu K, Saito HK, Matsuda T. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg 1997; 132: 1320-5.
19. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28: 1062-6.
20. Gruson D, Hilbert G, Vargas F et al. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000; 162: 837-43.
21. Frank MO, Batteiger BE, Sorenson SJ et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement programme. Clin Perform Qual Health Care 1997; 5: 180-8.
22. Geissler A,Gerbeaux P, Granier I et al. Rational useof antibiotics in the intensive care unit: Impact on microbial resistance and costs. Intensive Care Med 2003; 29: 1-2.
23. Smith DW. Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 1999; 19: S129-32.
24. Crowcroft NS, Ronvaux O, Monnet DL et al. MRSA and antimicrobial use in Belgium Infect Control Hosp Epidemiol 1999; 20: 31-6.
25. Washio M, Mizoue T, Kajioka T et al. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a Japanese geriatric hospital. Public Health 1997;119: 187-90.
26. Khan OA, Weston VC, Scammell BE. Methicillin-resistant Staphylococcus aureus incidence and outcome in patients with neck of femur fractures. J Hosp Infect 2002; 51: 185-8.
27. Muller AA, Mauny F, Bertin M et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003; 36: 971-8.
28. Grundmann H. Methicillin-resistant Staphylococcus aureus in a teaching hospital: Investigation of nosocomial transmission using a matched case-control study. Dissertation 1997. London School for Tropical Medicine and Hygiene, London, UK.
29. Monnet DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: Possible implications for control. Infect Control Hosp Epidemiol 1998; 19: 552-9.
30. Dziekan G, Hahn A, Thune K et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: Investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000; 46: 263-70.
31. Harbath S, Harris AD, CarmeliYet al. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin Infect Dis 2001; 33: 1462-8.
32. Hori S, Sunley R, Tami A et al. The Nottingham Staphylococus aureus population study: Prevalence of MRSA among the elderly in a university hospital. J Hosp Infect 2002; 50: 19-25.
33. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: Effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis Epidemiol Infect 2001; 127: 443-50.
34. Drinka PJ, Stemper ME, Gauerke CD et al. Is methicillin-resistant Staphylococcus aureus more contagious than methicillin-susceptible S. aureus in a surgical intensive care unit? Infect Control Hosp Epidemiol 2004; 25: 363-4.
35. Harbath S, Liassine N, Dharan S et al. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31: 1380-5.
36. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-86.
37. Knudsen AM, Rosdahl VT. The decline of methicillin resistance among Danish Staphylococcus aureus strains. Infect Control Hosp Epidemiol 1991; 12: 83-8.
38. Ayliffe GAJ, Lilly HA, Lowbury EJL. Decline of the hospital Staphylococcus? Incidence of multiresistant Staph. aureus in three Birmingham hospitals. Lancet 1979; i: 536-41.
39. Hoiby N, Jarlov JO, Kemp M et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349: 167-9.
40. Oppenheim BA, Hartley JW, Lee W et al. Outbreak of coagulase negative staphylococci highly resistant to ciprofloxacin in a leukaemia unit BMJ 1989; 299: 294-7.
41. Chang S, Sievert D, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New Engl J Med 2003; 348: 1342-7.
42. Clark NC, Weigel LM, Patel JB et al. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005; 49: 470-2.
43. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-46.
44. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-32.
45. Cartolano GL, Cheron M, Benabid D et al. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004; 10: 448-51.
46. Nonhoff C, Denis O, Struelens M. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clin Microbiol Infect 2005; 11: 214-20.
47. Brown DFJ, Edwards DI, Hawkey PM et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 2005; 56: 1000-18.
48. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
49. Aucken HM, Ganner M, Murchan S et al. A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J Antimicrob Chemother 2002; 50: 171-5.
50. Bertrand X, Hocquet D, Thouverez M et al. Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France. Clin Microbiol Infect 2003; 22: 504-6.
51. Drew RH, Perfect JR, Srinath L et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2002; 46: 775-84.
52. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections Int J Antimicrob Agents 2000; 16 Suppl 1: 31-4.
53. Sander A, Beiderlinden M, Schmid EN et al. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 2002; 28: 1157-60.
54. Sakoulas G, Moise-Broder PA, Schentag JJ et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 2004; 42: 2398-402.
55. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
56. Guidelines for the prevention and control of methicillin-resistant Staphylococcus aureus in long-term care facilities. Sioux Falls task force on antimicrobial resistance. SDJ Med 1999; 52: 235-40.
57. Guidelines for management of patients with methicillin-resistant Staphylococcus aureus in acute care hospitals and long-term care facilities. The MRSA Interagency Advisory Committee in conjunction with the Connecticut Department of Public Health and Addiction Services. Conn Med 1993; 57: 611-7.
58. Vandenbroucke-Grauls CMJE for the Working Party. Management Policy for Methicillin-Resistant Staphylococcus aureus. Guideline of the Working Party Infection Prevention. http://www.srga.org/MRB/Holland_2001.doc, 2001 (4 October 2005, date last accessed).
59. Guidelines for control and prevention of methicillin-resistant Staphylococcus aureus transmission in Belgian Hospitals. Groupement pour le Despitage, l'Etude et la Prevention des Infections Hospitalieres. Acta Clin Belg 1994; 49: 108-13.
60. Cosgrove S, Sakoulas G, Peremcevitch EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-9.
61. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among haemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26: 175-83.
62. Blot SI, Vandewoude KH, Hoste EA et al. Outcome and attributable mortality in critically ill patients with bacteraemia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162: 2229-35.
63. Harbath S, Rutschmann O, Sudre P et al. Impact of methicillin resistance on the outcome of patients with bacteraemia caused by Staphylococcus aureus. Arch Intern Med 1998; 158: 182-9.
64. Engemann JJ, Carmeli Y, Cosgrove S et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36: 592-8.
65. Melzer M, Eykyn SJ, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteraemia. Clin Infect Dis 2003; 37: 1453-60.
66. Romero-Vivas J, Rubio J, Fernandez C et al. Mortality associated with nosocomial bacteraemia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21: 1417-23.
67. Stamm AM, Long MN, Belcher B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant Staphylococcus aureus. Am J Infect Control 1993; 21: 70-4.
68. Kim S-H, Park W-B, Lee K-D et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54: 489-97.
69. Lodise TP, MacKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteraemia. Clin Infect Dis 2003; 36: 1418-23.
70. Gonzalez C, Rubio M, Romero-Vivas J et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-7.
71. Mylotte JM, Tayara A. Staphylococcus aureus bacteraemia, predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000; 31: 1170-4.
72. Jensen AG, Wachmann CH, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteraemia: A prospective study of 278 cases. Ann Intern Med 2002; 162: 25-32.
73. Chang F-Y, Peacock JE, Musher DM et al. Staphylococcus aureus bacteraemia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003; 82: 333-9.
74. Fowler VG,Justica A, Moore C et al. Risk factors forhematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteraemia. Clin Infect Dis 2005; 40: 695-703.
75. Johnson LB, Almoujahed MO, Ilg K et al. Staphylococcus aureus bacteremia: Compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 782-9.
76. Noone P. Use of antibiotics: Aminoglycosides. BMJ 1978; 2: 549-52.
77. Johnson AP, Aucken HM, Cavendish S et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: Analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001; 48: 143-4.
78. BSAC. Resistance Surveillance. 2005. http://www.bsacsurv.org.uk (4 October 2005, date last accessed).
79. Speller DCE, Johnson AP, James D. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid England and Wales, 1989-95. Lancet 1997; 350: 323-5.
80. Morrison D. MRSA - changing epidemiology and new threats. SCIEH Weekly Report 2003; 37: No 2003/12: 2-4.
81. Jonas D, Towner KJ, Loerwald M et al. Diversity of Staphylococcus aureus strains isolated from two European regions with different prevalences of methicillin resistance. Eur J Clin Microbiol Infect Dis 2002; 21: 880-3.
82. Walker J, Borrow R, Goering RV et al. Subtyping of methicillin-resistant Staphylococcus aureus isolates from the North-West of England: A comparison of standardised pulsed-field gel electrophoresis with bacteriophage typing including an inter-laboratory reproducibility study. J Med Microbiol 1999; 48: 297-301.
83. Moore PCL, Lindsay JA. Molecular characterisation of the dominant UK methicillin-resistant Staphylococcus aureus strains EMRSA-15 and EMRSA-16. J Med Microbiol 2002; 51: 516-22.
84. Gordts B, Firre E, Legrand J-C et al. National guidelines for the judicious use of glycopeptides in Belgium. Clin Microbiol Infect 2000; 6: 585-92.
85. Lacy MK,Tessier PR, Nicolau DP et al. Comparison of vancomycin pharmacodynamics (1g every 12 or 24 h) against methicillin-resistant staphylococci. Int J Antimicrob Agents 2000; 15: 25-30.
86. Cohen E, Dadashev A, Drucker M et al. Once daily versus twice daily intravenous administration of vancomycin for infections in hospitalised patients. J Antimicrob Chemother 2002; 49: 155-160.
87. Davey PG,Williams AH.Teicoplanin monotherapyof serious infections caused by Gram-positive bacteria: A re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial. J Antimicrob Chemother 1991; 27 Suppl B: 51-60.
88. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79-87.
89. MacGowan A, McMullin C, White LO et al. Serum monitoring of teicoplanin. J Antimicrob Chemother 1992; 30: 399-402.
90. Darley ESR, MacGowan AP. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect 2004; 10: 62-9.
91. Harding I, MacGowan AP, White LO et al. Teicoplanin therapy for Staphylococcus aureus septicaemia: Relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000; 45: 835-41.
92. Wilson APR, Gaya H. Treatment of endocarditis with teicoplanin: A retrospective analysis of 104 cases. J Antimicrob Chemother 1996; 38: 507-21.
93. Cepeda JA, Whitehouse Y, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: A randomized double-blind multicentre study. J Antimicrob Chemother 2004; 53: 345-55.
94. Tobin CM, Darville JM, Thompson AH et al. Vancomycin therapeutic drug monitoring: Is there a consensus view? The results of a UK National External Quality Assessment Scheme (UKNEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother 2002; 50: 713-8.
95. Saunders NJ. Why measure peak vancomycin levels? Lancet 1994; 344: 1748-50.
96. Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995; 36: 279-82.
97. Mellor JA, Kingdom J, Cafferkey MT et al. Vancomycin toxicity: A prospective study. J Antimicrob Chemother 1985; 15: 773-80.
98. Rybak MJ, Cappelletty DM, Ruffing MJ et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for Gram-positive infections. In Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract A46. American Society for Microbiology, Washington, DC, USA.
99. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin concentrations with outcome in patients with Gram-positive bacteraemia. Pharmacother 1995; 15: 85-91.
100. Glover ML, Cole E, Wolsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care 2000; 15: 1-4.
101. Miles MV, Li L, Lakkis H et al. Special considerations for monitoring vancomycin concentrations in paediatric patients. Ther Drug Monit 1997; 19: 265-70.
102. Lodise TP, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteraemia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003; 24: 655-61.
103. Eron LJ, Lipsky BA, Low DE. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl S1: I3-17.
104. Ruhe JJ, Monson T, Bradsher RW et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: Case series and review of the literature. Clin Infect Dis 2005; 40: 1429-34.
105. Chattopadhay B, Harding E. In vitro minocycline activity against tetracycline-resistant Staphylococcus aureus. Lancet 1975; I: 405.
106. Rich G, Davidson J. Minocycline sensitivity related to the phage type of multiply resistant staphylococci. J Clin Pathol 1975; 28: 450-2.
107. Voss A, Milatovic D, Wallrauch-Schwarz C et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-5.
108. Marone P, Cancia C, Andreoni M et al. Treatment of bone and soft tissue infections with teicoplanin. J Antimicrob Chemother 1990; 25: 435-9.
109. Turpin PJ, Taylor GP, Logan MN et al. Teicoplanin in the treatment of skin and soft tissue infections. J Antimicrob Chemother 1988; 21 Suppl A: 117-22.
110. Bochud-Gabellon I, Bergamey C. Teicoplanin a new antibiotic effective against Gram-positive bacterial infections of the skin and soft tissues. Dermatologica 1988; 176: 29-38.
111. Stevens DS, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 2002; 34: 1481-90.
112. Moise PA, Forrest A, Birmingham MC. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of or who have failed to respond to vancomycin. J Antimicrob Chemother 2002; 50: 1017-26.
113. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infection. J Antimicrob Chemother 2004; 53: 335-44.
114. Lipsky BA, Itani K, Norden C et al. Treating foot infections in diabetic patients, a randomized multicentre open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
115. Li Z, Willke RJ, Pinto LA et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized multicenter trial. Pharmacotherapy 2001; 21: 263-74.
116. Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health outcomes: Does reducing the length of hospital stay matter? J Antimicrob Chemother 2003; 52 Suppl S2: Ii37-44.
117. Weigelt J, Kaafarani HMA, Itani KMF et al. Linezolid eradicates MRSA better than vancomycin for surgical-site infections. Am J Surg 2004; 188: 760-88.
118. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
119. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: Evidence and opinion Clin Infect Dis 2003; 36: 473-81.
120. Leighton A, Gottlieb AB, Dorr M-B et al. Tolerability pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 940-5.
121. Seltzer E, Dorr M-B, Goldstein Bo et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infection. Clin Infect Dis 2003; 37: 1298-303.
122. Van-Bambeke F, Van Laethem Y, Courvalin P et al. Glycopeptide antibiotics: From conventional molecules to new derivatives. Drugs 2004; 64: 913-36.
123. Van-Bambeke F. Glycopeptides in clinical development: Pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004; 4: 471-8.
124. Faoagali JL, Thong ML, Grant D. Ten years' experience with methicillin-resistant Staphylococcus aureus in a large Australian hospital. J Hosp Infect 1993; 20: 113-9.
125. Gottlieb T, Mitchell D. The independent evolution of resistance to ciprofloxacin rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995). Australian Group for Antimicrobial Resistance (AGAR). J Antimicrob Chemother 1998; 42: 67-73.
126. Maple PAC, Hamilton-Miller JMT, Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet 1989; I: 537-9.
127. Parras F, Guerrero M del C, Bouza E et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 175-9.
128. Roccaforte JS, Bittner MJ, Stumpf CA et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin and bacitracin. Am J Inf Control 1988; 16: 141-6.
129. Walsh TJ, Standiford HC, Eboli AC et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprimsulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993; 37: 1334-42.
130. Boelaert JR, van Landuyt HW, Gordts BZ et al. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients, the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996; 17: 809-11.
131. Peacock SJ, Mandal S, Bowler ICJW. Preventing Staphylococcus aureus infection in the renal unit. Quart J Med 2002; 95: 405-10.
132. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM et al. Surgical site infections in orthopaedic surgery: The effect of mupirocin nasal ointment in a double-blind randomized placebo-controlled study Clin Infect Dis 2002; 35: 353-358.
133. Conly JM Johnston BL. Mupirocin - are we in danger of losing it? Can Journ Infect Dis 2002; 13: 157-9.
134. Townsend DE, Ashdown N, Greed LC et al. Transposition of gentamicin resistance to staphylococcal plasmids encoding resistance to cationic agents. J Antimicrob Chemother 1984; 14: 115-24.
135. Tennent JM, Lyon BR, Gillespie MT et al. Cloning and expression of Staphylococcus aureus plasmid-mediated quaternary ammonium resistance in Escherichia coli. Antimicrob Agents Chemother 1985; 27: 79-83.
136. Brumfitt W, Dixson S, Hamilton-Miller JMT. Resistance to antiseptics in methicillin and gentamicin resistant Staphylococcus aureus. Lancet 1985; II: 1442-3.
137. Irizarry L, Merlin T, Rupp J et al. Reduced susceptibility of methicillin-resistant Staphylococcus aureus to cetylpyridinium chloride and chlorhexidine. Chemotherapy 1996; 2: 248-52.
138. Cookson BD, Farrelly H, Stapleton P et al. Transferable resistance to triclosan in MRSA. Lancet 1991; 337: 1548-9.
139. Fraise AP. Susceptibility of antibiotic-resistant cocci to biocides. J Appl Bacteriol 2002; 92: 158S-62S.
140. Van der Auwera P, Klastersky J, Thys JP et al. Double-blind placebo-controlled study of oxacillin combined with rifampicin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985; 28: 467-72.
141. Canawati HN, Tuddenham WJ, Sapico FL et al. Failure of rifampin to eradicate methicillin-resistant Staphylococcus aureus colonization. Clin Ther 1982; 4: 526-31.
142. Chang S-C, Hsieh S-M, Chen M-L et al. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis 2000; 36: 131-6.
143. Clumeck N, Marcelis L, Aniri-Lamraski MH et al. Treatment of severe staphylococcal infections with a rifampicin-minocycline combination. J Antimicrob Chemother 1994; 13 Suppl C: 17-22.
144. Darouiche R, Wright C, Hamill R et al. Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocyclinerifampin and topical mupirocin. Antimicrob Agents Chemother 2003; 35: 1612-5.
145. Eng RHK, Smith SM, Tillem M et al. Rifampicin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection. Arch Intern Med 1988; 145: 146-8.
146. Muder RR, Boldin M, Brennen C et al. A controlled trial of rifampicin minocycline and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother 1994; 34: 189-90.
147. Jensen K. Methicillin resistant staphylococci. Lancet 1968; II: 1078.
148. Shanson DC. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus. J Antimicrob Chemother 1990; 25 Suppl B: 15-21.
149. Burnie J, Matthews R, Jiman-Fatami A et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: Evidence of resistance to vancomycin. Clin Infect Dis 2000; 31: 684-9.
150. Garaud JJ, Regnier B, Lassoued K et al. Treatment of severe staphylococcal infections: Failure of rifampicin in combination therapy. Presse Medicale 1985; 14: 1013-6.
151. Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: In vitro-in vivo correlations. J Infect Dis 1985; 151: 157-65.
152. Lucet J-C, Herrman M, Rohner P et al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34: 2312-7.
153. Fantin B, LeClerq R, Duval J et al. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 2466-9.
154. Svensson E, Honberger H, Nilsson M et al. Factors affecting development of rifampicin resistance in biofilm-producing Staphylococcus epidermidis. J Antimicrob Chemother 1997; 39: 817-20.
155. McAllister TA. Treatment of osteomyelitis. Br J Hosp Med 1974; 12: 535-45.
156. Markowitz N, Quinn RL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8.
157. Levin TP, Suh B, Axelrod P et al. Potential clindamycin resistance in clindamycin-susceptible erythromycin-resistant Staphylococcus aureus, report of a clinical failure. Antimicrob Agents Chemother 2005; 49: 1222-4.
158. Frank AL, Marcinak JF, Mangat PD et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis Journal 2002; 21: 530-4.
159. Thouverez M, Muller A, Hocquet D et al. Relationship between molecular epidemiology and antibiotic susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) in a French teaching hospital. J Med Microbiol 2003; 52: 801-8.
160. Nasim A, Thompson MM, Naylor AR et al. The impact of MRSA on vascular surgery. Eur J Endovasc Surg 2001; 22: 211-4.
161. Taylor MD Napolitano LM. Methicillin-resistant Staphylococcus aureus infections in vascular surgery: Increasing prevalence Surg Infect 2004; 5: 180-7.
162. Naylor AR, Hayes PD, Darke S. A prospective audit of complex wound and graft infections in Great Britain and Ireland: The emergence of MRSA. Eur J Vasc Endovasc Surg 2001; 21: 289-94.
163. Murphy GJ, Pararajasingam R, Nasim A et al. Methicillin-resistant Staphylococcus aureus infection in vascular surgery patients. Ann R Coll Surg Engl 2001; 83: 158-63.
164. Braithwaite BD, Davies B, Heather BP et al. Early results of a randomised trial of rifampicin-bonded Dacron grafts for extra-anatomic vascular reconstruction. Br J Surg 1998; 85: 1378-81.
165. Coggia M, Goueau-Brissonniere O, Leflon V et al. Experimental treatment of vascular graft infection due to Staphylococcus epidermidis by an in situ replacement with a rifampicin-bonded polyester graft. Ann Vasc Surg 2001; 15: 421-9.
166. Koshiko S, Sasajima T, Muraki S. Limitations in the use of
167. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-72.
168. Piercy EA, Barbaro D, Luby JP et al. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 1989; 33: 128-30.
169. Dacquet V. Treatment of bone and joint infection with teicoplanin: A retrospective analysis of 50 cases. Int J Antimicrob Agents 1996; 7, 49-51.
170. Cafferkey MT, Hone R, Coleman D et al. Methicillin-resistant Staphylococcus aureus in Dublin 1971-84. Lancet 1985; II: 705-8.
171. Graninger W, Wenisch C, Wiesinger E et al. Experience with out-patient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 643-7.
172. Graziani AL, Lawson LA, Gibson GA et al. Vancomycin concentrations in infected and non-infected human bone. Antimicrob Agents Chemother 1988; 32: 1320-2.
173. Chuard C, Herrrmann M, Vaudaux P et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combination. Antimicrob Agents Chemother 1991; 35: 2611-6.
174. Dworkin R, Modin G, Kunz S et al. Comparative efficacies of ciprofloxacin, pefloxacin and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990; 34: 1014-6.
175. Brandt CM, Sistrunk WW, Duffy MC et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997; 24: 914-9.
176. Tattevin P, Cremieux A-C, Pottier P et al. Prosthetic joint infection: when can prosthesis salvage be considered? Clin Infect Dis 1999; 29: 292-5.
177. Youngman JR, Ridgway G, Haddad FS. Antibiotic loaded cement in revision joint replacement. Hosp Med 2003; 64: 613-6.
178. Gerson SL. Haematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6.
179. Birmingham MC, Rayner CR, Flavin SM et al. Linezolid for the treatment of multidrug-resistant Gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68.
180. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram-positive prosthetic joint infection. J Antimicrob Chemother 2005; 55: 387-90.
181. Chater EH, Flynn J, Wilson AL. Fucidin levels in osteomyelitis. J Ir Med Assoc 1972; 65: 506-8.
182. Pahle JA. Experiences with fucidin in the treatment of osteomyelitis Acta Orthop Scand 1969; 40: 675.
183. Hierholzer G, Rehn J, Knothe H et al. Antibiotic therapy of chronic post-traumatic osteomyelitis. J Bone Joint Surg 1974; 56B: 721-9.
184. Sandeman JC, Percival A. Fusidic acid in the management of osteomyelitis. In: Hejzlar M, Semonsky M, Masak S eds. Advances in Antimicrobial and Antineoplastic Chemotherapy. Munich: Urban and Schwarzenburg, 1972; 1241-3.
185. Amorena B, Gracia E, Monzon M et al. Antibiotic susceptibility assay for S. aureus in biofilms developed in vitro. J Antimicrob Chemother 1999; 44: 43-55.
186. Drancourt M, Stein A, Argenson JN et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 2004; 39: 235-40.
187. Cox RA, Conquest C, Mallaghan C et al. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage type (EMRSA-16). J Hosp Infect 1995; 29: 87-106.
188. Melchior NH. Combined in vitro activity of fusidic acid and rifampicin against methicillin-resistant Staphylococcus aureus strains. In: Ishigami J, ed. Proceedings of the 14th International Congress of Chemotherapy, Kyoto. Tokyo: University of Tokyo Press, 1985; 582-3.
189. Martinez-Aguilar G, Hammerman WA, Mason EO et al. Clindamycin treatment of invasive infections caused by community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22: 593-8.
190. Stein A, Bataille JF, Drancourt M et al. Ambulatory treatment of mutidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-91.
191. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25: 425-30.
192. Khairulddin N,Bishop L,Lamagni TL et al. Emergence of methicillin resistant Staphylococcus aureus (MRSA) bacteraemia among children in England and Wales 1990-2001. Arch Dis Child 2004; 89: 378-9.
193. Keane CT, Cafferkey MT. Re-emergence of methicillin-resistant Staphylococcus aureus causing severe infection. J Hosp Infect 1984; 9: 6-16.
194. Myers JP, Linnemann CC, Jr. Bacteraemia due to methicillin-resistant Staphylococcus aureus. J Infect Dis 1982; 145: 532-6.
195. Fortun J, Navas E, Martinez-Beltran J et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33: 120-5.
196. Glupczynski Y, Lagast H, Van der Auwera P et al. Clinical evaluation of teicoplanin for therapy of severe infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 1986; 29: 52-7.
197. Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991; 27 Suppl B: 69-73.
198. Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991; 35: 451-7.
199. Rybak MJ, Abote BJ, Kang SL et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55.
200. Fridkin SK, McDougal LK, Mohammed J et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin United States 1997-2001. Clin Infect Dis 2003; 36: 429-39.
201. Linares J. The VISA/GISA problem, therapeutic implications. Clin Microbiol Infect 2001; 7 Suppl 4: 8-15.
202. Hershberger E, Donabedian S, Konstantinou K et al. Quinupristindalfopristin resistance in Gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004; 38: 92-8.
203. Pillai SK, Sakoulas G, Eliopoulos GM et al. Linezolid resistance in Staphylococcus aureus: Characterization and stability of resistant phenotype. J Infect Dis 2002; 186: 1603-7.
204. Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190: 311-7.
205. Mangili A, Bica I, Snydman DR et al. Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40: 1058-60.
206. Elliott TSE, Foweraker J, Gould FK et al. Guidelines for the antibiotic treatment of endocarditis in adults: Report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971-81.
207. Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteraemia associated with a removable focus of infection. Ann Intern Med 1976; 84: 558-60.
208. Rosen AB, Fowler VG, Corey GR et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteraemia. Ann Intern Med 1999; 130: 810-20.
209. Fowler VG, Li J, Corey GR et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteraemia: Experience in 103 patients. J Am Coll Cardiol 1997; 30: 1072-8.
210. Miall LS, McGinley NT, Brownlee KG et al. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001; 84: 160-2.
211. Gilligan PH, Gage PA, Welch DF et al. Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. J Clin Microbiol 1987; 25: 1258-61.
212. Rubinstein E, Cammarata SK, Oliphant TH et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalised patients with nosocomial pneumonia: A randomised double-blind multicentre study. Clin Infect Dis 2001; 32: 402-12.
213. Wunderink RG, Cammarata SK, Oliphant TH et al. Continuation of a randomized double-blind multi-center study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-92.
214. Wunderink RG, Rello J, Cammarata SK et al. Analysis of two double blind studies of patients with MRSA nosocomial pneumonia. Chest 2003; 124: 1789-97.
215. Kollef MH, Rello J, Cammarata SK et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia, retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94.
216. Jantausch BA, Deville JG, Adler S et al. Linezolid for the treatment of children with bacteraemia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22: S164-71.
217. Fagon J, Patrick H, Haas DW et al. Treatment of Gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161: 753-62.
218. Carney M, Peyman GA, Fiscella R et al. The intraocular penetration and retinal toxicity of teicoplanin. Ophthalmic Surg 1988; 19: 119-23.
219. Chadwick AJ, Jackson B. Intraocular penetration of the antibiotic fucidin. Br J Ophthalmol 1969; 53: 269.
220. Tabbora KF, O'Connor GR. Ocular tissue absorption of clindamycin phosphate. Arch Ophthalmol 1975; 93: 1180-5.
221. Fiscella RG, Lai WW, Khan M et al. Aqueous and vitreous penetration of linezolid after oral administration. Ophthalmology 2004; 111: 1191-5.
222. Marrakchi-Benjaafar S, Cochereau I, Pocidalo J-J et al. Systemic prophylaxis of experimental staphylococcal endophthalmitis: Comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin and amikacin. J Infect Dis 1995; 172: 1312-6.
223. Fukuda M, Ohashi H, Matsumoto C et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus ocular surface infection efficacy of chloramphenicol drops. Cornea 2002; 21 Suppl 2: 586-9.
224. Roche M, Humphreys H, Smyth E et al. A twelve-year review of central nervous bacterial abscesses: Presentation and aetiology. Clin Microbiol Infect 2003; 9: 803-9.
225. DeLouvois J, Gortvai P, Hurley R. Bacteriology of abscesses of the central nervous system: A multicentre prospective study. BMJ 1977; 3: 981-7.
226. Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine-clindamycin vs pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22: 268-75.
227. Rountree PM, Lowenthal J, Tedder E et al. Staphylococcal wound infection: The use of neomycinand chlorhexidine (Naseptin) nasal cream in its control. Med J Australia 1962; 49: 367-70.
228. Williams JR, Talbot EC, Maughan E. Hospital outbreak of crossinfection due to Staphylococcus pyogenes phage type 80. BMJ 1959; I: 1374-8.
229. Stokes EJ, Milne SE. Effect of Naseptin cream prophylaxis on staphylococcal infection in adult surgical wards and infant nurseries. J Hyg(Lond) 1962; 60: 209-15.
230. Henderson R, Williams REO. Nasal disinfection in prevention of post-operative staphylococcal infection of wounds. BMJ 1961; 2: 330-3.
231. Stokes EJ, Richards BM, Richards JDM et al. Control of hospital staphylococci. Lancet 1965; II: 197-201.
232. Editorial. Staphylococci resistant to neomycin and bacitracin. Lancet 1965; I, 421.
233. Shooter RA. Ward practice. In: Williams REO, Shooter RA eds. Infection in Hospitals: Epidemiology and Control. Oxford: Blackwell, 1963; 221-30.
234. Williams REO, Blowers R, Garrod LP et al. In: Hospital Infection, Causes and Prevention, 2nd edition. London: Llloyd-Luke, 1966; 77-115.
235. Dryden MS, Dailly S, Crouch M. A randomised, controlled trial of tea tree topical preparations versus a standard topical regimen for clearance of MRSA colonization. J Hosp Infect 2004; 56: 283-6.
236. Hill RHR, Duckworth GJ, Casewell MW. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. J Antimicrob Chemother 1988; 22: 377-84.
237. Mody L, Kauffman CA, McNeill SA et al. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 1467-74.
238. Harbarth, S, Dharan, S, Liassine, N et al. Randomized placebo-controlled double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999: 43: 1412-6.
239. Mayall B, Martin R, Keenan AM et al. Blanket use of intranasal mupirocin for outbreak control and long-term prophylaxis of endemic methicillin-resistant Staphylococcus aureus in an open ward. J Hosp Infect 1996; 32: 257-66.
240. Hitomi S, Kubota M, Mori N et al. Control of methicillin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit by unselective use of nasal mupirocin ointment. J Hosp Infect 2000; 46: 123-9.
241. Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term care facility with the use of mupirocin ointment. Am J Med 1993; 84: 371-8.
242. Loeb M, Main C, Walker-Dilks C et al. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization (Cochrane Review). In: The Cochrane Library Issue 3. Chichester: John Wiley & Sons Ltd, 2004.
243. Scanvic A, Denuc L, Gaillon S et al. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 2001; 32: 1393-8.
244. Walker ES, Vasquez JE, Dula R et al. Mupirocin-resistant methicillin-resistant Staphylococcus aureus: Does mupirocin remain effective? Infect Control Hosp Epidemiol 2003; 24: 342-6.
245. Udo EE, Jacob LE, Mathew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin reistance. J Med Microbiol 2001; 50: 909-15.
246. Finlay JE, Miller L, Poupard JA. Interpretative criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997; 41: 1137-9.
247. Semret M, Miller MA. Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains. Infect Control Hosp Epidemiol 2001; 22: 578-80.
248. Bernard L, Vaudaux A, Stern R et al. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: Lack of emergence of glycopeptide resistance. Infect Control Hosp Epidemiol 2003; 24: 650-4.
249. Silvestri L, Milanese M, Oblach L et al. Enteral vancomycin to control methicillin-resistant Staphylococcus aureus outbreak in mechanically ventilated patients. Am J Infect Control 2002; 30: 391-9.
250. Maraha B, van Halteren J, Verzijt JM et al. Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin. Clin Microbiol Infect 2002; 8: 671-5.
251. De la Cal MA, Cerda E, Van Saene HK et al. Effectiveness and safety of enteral vancomycin to control endemicity of methicillin-resistant Staphylococcus aureus in a medical/surgical intensive care unit. J Hosp Infect 2004; 56: 175-83.
252. Rimland D, Roberson B. Gastrointestinal carriage of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 1986; 24: 137-8.
253. Harbath S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002; 46: 1619-28.
254. Carmeli Y, Samore MH, Huskins WC. The association between vancomycin treatment and hospital-acquired vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1999; 159: 2461-8.
255. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002; 8: 802-7.
256. Furuno JP, Harris AD, Wright M-O et al. Prediction rules to identify patients with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci upon hospital admission. Am J Infect Control 2004; 32: 436-40.
257. Kato T, Hayasaka S. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci from conjunctivas of preoperative patients. Jpn J Ophthalmol 1998; 42: 461-5.
258. Wilcox MH, Hall J, Pike H et al. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infection. J Hosp Infect 2003; 54: 196-201.
259. Merrer J, Pisica-Donose G, Leneven M et al. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage among patients with femoral neck fractures: Implication for antibiotic prophylaxis. Infect Control Hosp Epidemiol 2004; 25: 515-7.
260. Dupeyron C, Campillo B, Bordes M et al. Clinical trial of mupirocin in the eradication of methicillin-resistant Staphylococcus aureus nasal carriage in a digestive disease unit. J Hosp Infect 2002; 52: 281-7.
261. Rowe-Jones DC, Peel ALG, Kingston RD et al. Single dose cefotaxime plus metronidazole versus three dose cefuroxime plus metronidazole as prophylaxis against wound infection in colorectal surgery: Multi-centre prospective randomised study. BMJ 1990; 300: 18-22.
262. Griffiths DA, Simpson RA, Shorey BA et al. Single-dose perioperative antibiotic prophylaxis in gastrointestinal surgery. Lancet 1976; II: 325-8.
263. Feathers RS, Lewis AAM, Sagor GR et al. Prophylactic systemic antibiotics in colorectal surgery. Lancet 1977; II: 4-8.
264. Murchan S, Aucken HM, O'Neill GL et al. Emergence, spread and characterization of phage variants of epidemic methicillin-resistant Staphylococcus aureus 16 in England and Wales. J Clin Microbiol 2004; 42: 5154-60.
265. Hammond CJ, Gill J, Peto TEA et al. Investigation of prevalence of MRSA in referrals to neurosurgery: Implications for antibiotic prophylaxis. Br J Neurosurg 2002; 16: 550-4.
266. Denis O, Deplano A, De Ryck R et al. Emergence and spread of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus in Belgian hospitals. Microb Drug Resist 2003; 9: 61-71.